Research Article
Study on miRNAs in Pan-Cancer of the Digestive Tract Based on the Illumina HiSeq System Data Sequencing

Chun-hui Lai, Xu-zhi Liang, Xiu-yun Liang, Sheng-jun Ma, Jun-guo Li, Ming-fang Shi, Xu Zhu, Hui-hua Lan, and Jiang-hui Zeng

1Department of Clinical Laboratory, The Third Affiliated Hospital of Guangxi Medical University/Nanning Second People’s Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
2Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
3Department of Clinical Laboratory, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region, China

Correspondence should be addressed to Hui-hua Lan; 119686274@qq.com and Jiang-hui Zeng; 705130251@qq.com

Received 26 May 2019; Revised 16 August 2019; Accepted 6 September 2019; Published 15 October 2019

Guest Editor: Guoku Hu

Copyright © 2019 Chun-hui Lai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. miRNA has gained attention as a therapeutic target in various malignancies. The proposal of this study was to investigate the biological functions of key miRNAs and target genes in cancers of the digestive tract which include esophageal carcinoma (ESCA), gastric adenocarcinoma (GAC), colorectal cancer (CRC), and rectal adenocarcinoma (READ). According to the data of the National Cancer Center of China (NCCR) [1], the total number of newly diagnosed cancers of the digestive system in China was 2,089,500 cases and 1,565,500 deaths in 2015. Also, over 2.7 million new cases of cancers of the digestive tract and 1.8 million deaths

1. Introduction
Cancer of the digestive tract is one of the most common malignancies in the world, and it is also a common high-risk malignancy in China, mainly including esophageal carcinoma (ESCA), gastric adenocarcinoma (GAC), colorectal cancer (CRC), and rectal adenocarcinoma (READ). According to the data of the National Cancer Center of China (NCCR) [1], the total number of newly diagnosed cancers of the digestive system in China was 2,089,500 cases and 1,565,500 deaths in 2015. Also, over 2.7 million new cases of cancers of the digestive tract and 1.8 million deaths
were estimated to occur in 2018. They were colorectal cancer (6.1%), stomach cancer (5.7%), and esophagus cancer (3.2%) with 1,096,601, 1,033,701, and 572,034 incidences, respectively [2]. The prognosis of cancers of the digestive tract is poor because of the advanced stage at the time of being diagnosed. Thus, early and timely diagnosis is of great importance for patients with cancers of the digestive tract which determines whether the patient can receive radical surgical treatment or not [3, 4]. Therefore, reliable biomarkers are urgently required for detection of the cancers of the digestive tract in primary stages to improve the adverse outcome of patients [5]. In this study, we aim to find potential biomarkers for early diagnosis and explore their molecular mechanisms in cancers of the digestive tract.

MicroRNA (miRNA) is an endogenous noncoding RNA with a length of about 22 nucleotides [6]. It plays an oncogene or tumor suppressor role in biological function by regulating target genes, which can inhibit the translation of protein via binding directly to specific sequences of target gene transcription through regulatory mechanisms including positive regulation of mRNA targets and induction of direct degradation of mRNA [7]. The dysregulated miRNA expression is correlated with human diseases, and some miRNAs also play a causal role in the biological processes of the tumor microenvironment [8]. All the above data indicated that miRNAs have the unique advantages as a biomarker because of their sensitive regulatory function and superior stability. More and more evidence has demonstrated that many key miRNAs participated in the initiation and progression of cancers of the digestive tract [9–11]. Therefore, the purpose of our study was to find the diagnostic and prognostic value of key miRNAs, and the biological function of target genes in cancers of the digestive tract needs to be better elucidated.

In this study, miRNA and mRNA expression profiles associated with ESCA, GAC, COAD, and READ were selected from The Cancer Genome Atlas (TCGA) database. TCGA includes comprehensive cancer genome data such as mutation, copy number variation, mRNA expression, miRNA expression, and methylation data. After identifying differentially expressed miRNAs (DEMIs), we estimated their diagnostic and prognostic value. Furthermore, we take the intersection of differentially expressed genes (DEGs) and the target genes predicted by miRWalk 2.0 and established miRNA-mRNA regulatory networks. Meanwhile, the relationship between miRNAs and their target genes was explored by constructing the regulated network. Furthermore, we investigated the target genes through bioinformatics methods including miRNAs-gene regulatory networks, protein-protein interaction (PPI) networks, gene ontology (GO) annotation, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and gene group RIDA analysis by Gene-Cloud of Biotechnology Information (GCBI) to explore molecular mechanisms of tumor development and give a new insight into cancers of the digestive tract molecular study.

2. Materials and Methods

2.1. Collection of DEMIs and DEMs in Cancers. The cancer genome data collected by TCGA can be divided into three levels. Level 1 represents the original sequencing data (fasta, fastq, etc.), level 2 comprises compared bam files, and level 3 comprises processed and standardized data. The Illumina HiSeq system high-throughput miRNA and mRNA expression profile data (level 3) and corresponding survival time clinicopathological data were obtained from TCGA in 2018, which included ESCA, GAC, COAD, and READ tissue samples and corresponding normal tissue samples. Genes with |log2 fold change (FC)| > 1 as well as P value < 0.05 were considered to be DEMIs and differentially expressed miRNAs (DEMIs). Since the data are publicly available, additional approval from the ethics committee was not needed in the present study.

2.2. Identification of DEMIs and DEMs in the Cancers of the Digestive Tract. The edgeR package in Bioconductor was used to screen the DEMIs and DEMs with |logFC| > 1 and adjusted P value < 0.05. We filtered the miRNAs from the above with |logFC| > 3 and adjusted P value < 0.05, and then we took the intersection in the upregulated or downregulated miRNAs, respectively, in the cancers of the digestive tract.

2.3. Screening of the miRNAs with Prognostic Value. The obtained DEMIs in ESCA, GAC, COAD, and READ were matched with a corresponding survival time and stage. After removing more than 10% of the missing values in above data, DEMIs were analyzed by the univariate Cox risk regression model to screen prognostic factors. Subsequently, we performed intersection of DEMIs associated with the prognosis of ESCA, GAC, COAD, and READ which were identified through the above univariate Cox risk regression model analysis, and DEMIs with significant prognostic value in cancers of the digestive tract were obtained. Kaplan–Meier analysis was used to demonstrate their prognostic significance.

2.4. Screening of the miRNAs with Diagnostic Value. DEMIs were extracted (|logFC| > 3, P < 0.05) from the above screened differentially expressed miRNAs in ESCA, GAC, COAD, and READ. The diagnostic value of miRNAs was evaluated by ROC curve analysis performed via the MedCalc software.

2.5. Prediction of the Target Genes of miRNAs. The potential target genes of miRNAs were predicted by miRWalk 2.0, which is a cross-prediction website that provides experimentally validated miRNA-target genes as well as target genes predicted by binding specific 3′-end-untranslated regions of specific miRNAs and other methods to predict target genes for miRNA. It contains 12 silico databases (miRWalk, Microt4, miRanda, miRBridge, miRDB, miRMap, miRNAMap, PicTar2, PITA, RNA22, RNAhybrid, and TargetScan). The source version and prediction mechanism of these databases are listed in Table 1.
2.6. Construction of the miRNA-mRNA Regulatory Networks.
Only the genes predicted by 5 or more databases were regarded as potential target genes for each DEMI. The intersection between the predicted genes mentioned above and DEMs of TCGA was considered target genes of DEMIs. Based on the principle of miRNAs negatively regulating their target genes, the miRNA-mRNA regulatory networks were constructed using Cytoscape 3.4.0 which is a public source network visualization as well as visualization analysis tool. The core of the software is the network, and the nodes are genes, proteins, or molecules, and the connection is the interaction between these biological structures.

2.7. PPI Network Construction. The STRING database (http://www.string-db.org/) is a large open-source database for searching the direct physical interaction and indirect functional correlation between known proteins and predictive proteins, with 2031 species, 9.6 million protein information, and 13.8 million protein interactions. Its connection lines use different color identifications to distinguish known interactions such as experimentally validated and predicted interactions and others. We constructed the PPI network of the target genes of DEMIs by using it.

2.8. GO Annotation, KEGG Pathway Analysis, and RIDA Analysis. To further investigate the functional annotation as well as signal pathways related to the target genes of DEMIs, we conducted GO annotation analysis and KEGG pathway analysis using DAVID (https://david.ncifcrf.gov/), a database with integrated biological information and analytical tools. GO annotation analysis contains 3 categories, including molecular function (MF), biological process (BP), and cellular component (CC), and the hierarchical structure of functional information was described in every catalog. KEGG is second to none in the study of molecular signaling pathways, which includes the GENES database with complete genomic information and sequences as well as the PATHWAY database with more complete functional information. We also performed a gene group RIDA analysis which includes related diseases, core networks, and related transcription factors by applying GCBI (https://www.gcbi.com.cn/). GCBI is a platform which contains more than 1.2 million samples of 20 TB of information data, and it provides many services such as genetic analysis, data analysis, and molecular medical information solution.

2.9. Validation by Gene Expression Omnibus DataSets. The clinical roles of the six miRNAs were validated by collecting the relevant miRNA microarrays from Gene Expression Omnibus (GEO) DataSets. Differences in miRNA expression levels between different groups were assessed using Student’s t-test. The ROC curve analysis of the miRNAs was performed by the MedCalc software.

3. Results
3.1. DEMIs and DEMs in Cancers of the Digestive Tract on TCGA Database. After obtaining miRNA expression data of ESCA (90 cases and 13 normal samples), GAC (446 cases and 45 normal samples), COAD (457 cases and 8 normal samples), and READ (162 cases and 3 normal samples), the R language edgeR package was used for difference analysis and screening (logFC > 1, P < 0.05). The results are shown in Figure 1. In the same way, mRNA expression data of ESCA (80 cases and 11 normal samples), GAC (375 cases and 32 normal samples), COAD (480 cases and 41 normal samples), and READ (167 cases and 10 normal samples) were analyzed. Because of the large amount of data, the DEMs were shown in a more intuitive volcanic map instead of a list (Figure 2).
3.2. Prognostic Significance of the DEMIs. We evaluated the prognostic value of three DEMIs by univariate Cox risk regression model analysis. The DEMIs above were further screened by matching with survival time and removing more than 10% missing values. 101 DEMIs related to ESCA, 140 DEMIs related to GAC, 296 DEMIs related to COAD, and 261 DEMIs related to READ were obtained. By identifying a number of prognostic values of miRNA molecular analysis by the univariate Cox risk regression model, DEMIs with prognostic values were obtained, among which 22 were related to ESCA, 22 to GAC, 22 to COAD, and 11 to READ (Table 2). After taking the intersection, miR-7-3 was found in ESCA and GAC intersection, miR-328 in GAC and COAD intersection, and miR-323a in COAD and READ intersection (Figure 3).

We found that the expression level of these 3 miRNAs associated with prognosis in cancers of the digestive tract had significant difference compared with each control sample group. The expression of miR-7-3 was greatly higher than that in four normal sample groups, the expression of miR-328 was all obviously lower than that in four normal sample groups, and the expression of miR-323a was lower in COAD and READ than that in the normal sample group (Figure 4). Subsequently, we performed survival analysis of miR-7-3, miR-328, and miR-323a by Kaplan–Meier analysis, and the results are shown in Figure 5. It was shown that the miR-7-3 high-expression group in ESCA had a lower survival rate than the low-expression group, while the high-expression group of miR-7-3 in GAC had a higher survival rate than the low one, which suggested miR-7-3 was a risk factor in ESCA and a protective factor in GAC. In COAD and GAC, the results indicated that the high-expression group of miR-328 had a lower survival rate than the low one, and miR-328 was a risk factor in COAD and GAC. The K-M survival curve of miR-323a in COAD and GAC showed that the miR-323a high-expression group had a higher survival rate than the low one, and miR-323a was a protective factor in READ. The HR value was $1.2207 > 1$, suggesting miR-323a as a risk factor in COAD. Meanwhile, the prognostic value of a diversity of clinicopathological parameters was also explored. It was demonstrated by univariate Cox regression analysis that gender, disease stage, N stage, M stage, lymphatic invasion, venous invasion, treatment outcome, neoplasm recurrence, residual tumor, and tumor status were associated with the prognosis of colon cancer (Supplementary Table 1).

3.3. Diagnostic Significance of the DEMIs. A total of 31 miRNAs (24 upregulated and 7 downregulated) in ESCA, 71 miRNAs (65 upregulated and 6 downregulated) in GAC, 200 miRNAs (146 upregulated and 54 downregulated) in COAD, and 225 miRNAs (139 upregulated and 86 downregulated) in READ were considered DEMIs by the standard of $|\log FC| > 3$ and $P < 0.05$ by the edgeR package. One upregulated miRNA (miR-552) and two downregulated miRNAs (miR-490 and miR-133a-2) were identified as DEMIs according to the intersection taken between upregulated and downregulated miRNAs in the cancers of the digestive tract (Figure 6). We found that the expression level of these 3
miRNAs in cancers of the digestive tract had significant difference compared with each control sample group. The expression of miR-552 was greatly higher than that in the normal sample group, and the expression of miR-490 and miR-133a-2 was obviously lower than that in the normal sample group (Table 3; Figure 7). We evaluated the diagnostic value of the three DEMIs by ROC curve analysis. The AUC of the three miRNAs is shown in Figure 8. The results indicated that three miRNAs exhibited high diagnostic value in READ and moderate diagnostic value in ESCA, GAC, and COAD. Interestingly, the AUC value of the three miRNAs was all biggest in READ, and miR-552 had the highest AUC of 1.0 in READ, which indicated favorable diagnostic value of the three miRNAs in READ.

**Figure 2:** Differential expression of the mRNA volcano map in four kinds of cancers of the digestive tract: (a) esophageal carcinoma (ESCA); (b) gastric adenocarcinoma (GAC); (c) colon adenocarcinoma (COAD); (d) rectal adenocarcinoma (READ). Among 6926 DEMs in ESCA tissues, 2515 were upregulated and 4411 were downregulated, while 11558 and 7922 were upregulated and downregulated, respectively, in 3636 DEMs in GAC tissues, and 205 were upregulated and 250 were downregulated among the 455 DEMs in COAD tissues. Of the 9335 READ DEMs, 5144 were upregulated and 4191 were downregulated. The volcano map was drawn by the R language gplots package. The difference in expression of upregulated miRNAs (logFC > 1, P < 0.05) was marked in red, and the difference in expression of downregulated miRNAs (logFC < −1, P < 0.05) was marked in green.

### 3.4. Prediction of Target Genes and Construction of miRNA-mRNA Regulatory Networks
We predicted potential target genes for miR-490-3p, miR-133a-3p, and miR-552-3p by miRWalk 2.0. Genes that can be predicted in 5 database resources at least were identified as potential target genes to intersect with DEMs obtained from TCGA. Since DEMs and target genes are negatively correlated under sequence complementation, we intersected the predicted potential target genes of upregulated DEMIs with common downregulated DEMIs obtained from TCGA and also the downregulated DEMIs’ predicted target genes with common upregulated DEMIs. miR-490-3p and miR-133a-3p were intersected with upregulated DEMIs. Meanwhile, miR-552-3p and downregulated DEMIs were intersected. Finally, 281
Table 2: Differential expression of miRNAs associated with the prognosis of ESCA, GAC, COAD, and READ.

| Cancer  | Name      | HR     | Lower  | Higher  | P    |
|---------|-----------|--------|--------|---------|------|
| ESCA    | miR-23b   | 0.589  | 0.422  | 0.821   | 0.002|
|         | miR-550a-1| 1.6032 | 1.193  | 2.154   | 0.002|
|         | miR-29c   | 0.7028 | 0.559  | 0.883   | 0.003|
|         | miR-550a-3| 1.6423 | 1.18   | 2.285   | 0.003|
|         | miR-550a-2| 1.5782 | 1.13   | 2.025   | 0.007|
|         | miR-3682  | 1.5101 | 1.114  | 2.047   | 0.008|
|         | miR-3074  | 1.5073 | 1.106  | 2.054   | 0.009|
|         | miR-421   | 1.5859 | 1.113  | 2.259   | 0.011|
|         | miR-503   | 1.432  | 1.084  | 1.892   | 0.012|
|         | miR-1301  | 1.5588 | 1.1    | 2.21    | 0.013|
|         | miR-7-2   | 1.2644 | 1.045  | 1.53    | 0.016|
|         | miR-7-3   | 1.2542 | 1.039  | 1.514   | 0.018|
|         | miR-18a   | 1.3229 | 1.043  | 1.678   | 0.021|
|         | miR-483   | 1.1883 | 1.025  | 1.377   | 0.022|
|         | miR-30e   | 0.5741 | 0.353  | 0.934   | 0.025|
|         | miR-935   | 1.1622 | 1.017  | 1.329   | 0.028|
|         | miR-767   | 1.066  | 1.005  | 1.131   | 0.033|
|         | miR-378c  | 0.7493 | 0.575  | 0.976   | 0.033|
|         | miR-28    | 0.6329 | 0.414  | 0.968   | 0.035|
|         | miR-143   | 0.7696 | 0.603  | 0.983   | 0.036|
|         | miR-133b  | 0.9134 | 0.839  | 0.995   | 0.038|
|         | miR-301b  | 1.2931 | 1.004  | 1.665   | 0.046|
| GAC     | miR-328   | 1.2993 | 1.111  | 1.519   | 0.001|
|         | miR-7-3   | 0.8867 | 0.824  | 0.954   | 0.001|
|         | miR-125a  | 1.3635 | 1.125  | 1.652   | 0.002|
|         | miR-365a  | 1.3167 | 1.082  | 1.603   | 0.006|
|         | miR-96    | 0.8544 | 0.764  | 0.956   | 0.006|
|         | miR-675   | 1.0864 | 1.024  | 1.152   | 0.006|
|         | miR-365b  | 1.3137 | 1.079  | 1.599   | 0.007|
|         | miR-877   | 0.909  | 0.847  | 0.976   | 0.008|
|         | miR-708   | 1.1873 | 1.043  | 1.351   | 0.009|
|         | miR-100   | 1.1213 | 1.027  | 1.224   | 0.01 |
|         | miR-200b  | 0.8592 | 0.764  | 0.966   | 0.011|
|         | miR-200c  | 0.8546 | 0.754  | 0.969   | 0.014|
|         | miR-145   | 1.126  | 1.022  | 1.241   | 0.017|
|         | miR-548v  | 1.1094 | 1.017  | 1.21    | 0.019|
|         | miR-217   | 1.1241 | 1.019  | 1.241   | 0.02 |
|         | miR-30a   | 1.153  | 1.021  | 1.302   | 0.022|
|         | miR-218-2 | 1.131  | 1.014  | 1.262   | 0.027|
|         | miR-218-1 | 1.1291 | 1.013  | 1.259   | 0.029|
|         | miR-187   | 1.0563 | 1.006  | 1.109   | 0.029|
|         | miR-139   | 1.1427 | 1.009  | 1.294   | 0.036|
|         | miR-216a  | 1.0778 | 1.005  | 1.156   | 0.036|
|         | miR-125b-1| 1.111  | 1.001  | 1.233   | 0.049|
overlapped genes in total were obtained (Figure 9). The miRNA-mRNA regulatory networks were established with miR-490-3p and its 49 target genes, miR-133a-3p and its 63 target genes, and miR-552-3p and its 179 target genes using the Cytoscape software (Figure 10). The PPI network was constructed with 281 target genes. According to the frequency of network connection, 22 hub genes (GNG7, CXCL12, GNAI1, LPAR1, PTGER3, APLN, CXCL11, GPER, CACNB2, COL11A1, COL1A1, COL4A1, COL5A2, COL5A3, GNAO1, SERPINH1, CDC6, F2RL2, KIT, P4HA3, PGF, and PTGFR) were obtained (Figure 11).

### 3.5. Biological Function Analysis of Overlapping Genes

To better understand the biological functions of the 281 overlapping genes, we performed the GO annotation and KEGG pathway analyses. All significant results of GO function analysis with 281 overlapping genes are listed in Table 4. These target genes mainly participate in the biological process (BP) including positive regulation of cell proliferation, cell migration, positive regulation of gene expression, and positive regulation of cell migration. For the term “cellular component” (CC), these genes were involved in the plasma membrane, extracellular region, cell surface, and cell junction. Moreover, the target genes were mainly involved in heparin binding, actin binding, growth factor activity, and extracellular matrix structural constituent classified by molecular function (MF) analysis. Furthermore, 15 significant pathways among these 281 target genes were obtained by KEGG pathway analysis ($P < 0.05$), and the
results indicated the target genes were significantly enriched in the PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, focal adhesion, and pathways in cancer (Table 5; Figure 12). These target genes were also performed for cluster radar analysis, including related diseases, core networks, and related transcription factors in RIDA analysis by GCBI. From the analysis result of related diseases, it was suggested that these genes were associated with tumor metastasis, adenocarcinoma, GAC, and colorectal cancer (CRC) (Figure 13). Core network analysis indicated the relationships of genes and gene proteins with interaction, activation, inhibition, phosphorylation, and ubiquitination (Figure 14). Transcription factor analysis showed that the transcription factor regulation contains DNA binding, activation, and inhibition (Figure 15).

3.6. Validation of These miRNAs Using Gene Expression Omnibus DataSets. The expression differences and expression trends of miR-7-3p, miR-323a, and miR-328 in CRC, ESCA, and GAC were verified by GSE89974, GSE114110, GSE93415, and GSE54397. Among them, miR-7-5p was a mature body of miR-7-3 (Figure 16). The expression differences and expression trends of miR-490-3p, miR-133a, and miR-552 in CRC, ESCA, and GAC were verified by GSE89974, GSE55856, GSE93415, GSE114110, GSE30070, and GSE66274 (Figure 17). Furthermore, their diagnostic values were verified by calculating the AUC value. The three areas under the ROC curves (AUCs) of miRNAs (miR-490-3p, miR-133a, and miR-552) were 0.758, 0.613, and 0.920 (CRC, ESCA, and GAC), 0.771, 1.000, and 0.761 (CRC, ESCA, and GAC), and 0.838, 0.809, and 0.715 (CRC, ESCA, and GAC) (Figure 18).

4. Discussion

Cancer of the digestive tract is a kind of cancer with high mortality due to its poor prognosis. Increasing evidence has demonstrated that miRNAs played a significant role in diverse tumors and were involved in many biological
Figure 5: K-M survival curve of miR-7-3, miR-328, and miR-323a in the cancers of the digestive tract—ESCA (esophageal adenocarcinoma), GAC (gastric adenocarcinoma), COAD (colon adenocarcinoma), and READ (rectal adenocarcinoma). K-M survival curve was drawn by the SPSS 19 software. The transverse coordinates represent the survival time (the number of days), and the ordinate represents the cumulative survival function. The blue color represents the low expression of the patient, and the green color represents the high expression of the patient. (a) ESCA miR-7-3. (b) GAC miR-7-3. (c) COAD miR-328. (d) GAC miR-328. (e) COAD miR-323a. (f) READ miR-323a.
Figure 6: Differential expression of the miRNA (|logFC| > 3, \( P < 0.05 \)) Venn map in adenocarcinoma of the digestive tract—ESCA (esophageal adenocarcinoma), GAC (gastric adenocarcinoma), COAD (colon adenocarcinoma), and READ (rectal adenocarcinoma). The upregulation of miRNAs in 4 kinds of digestive tract tumors obtained 1 intersection (miR-552), and 2 intersections (miR-490 and miR-133a-2) were obtained in downregulated miRNAs.

Table 3: Differential expression of miR-552, miR-490, and miR-133a-2 in adenocarcinoma of the digestive tract.

| ID     | Cancer | logFC  | logCPM   | P value | FDR     |
|--------|--------|--------|----------|---------|---------|
| miR-552| ESCA   | 4.91785| 5.680932 | 3.79E-05| 0.000781397|
|        | GAC    | 6.029278| 5.575829 | 4.84E-18| 1.81E-16 |
|        | COAD   | 5.570729| 7.551953 | 1.39E-11| 1.46E-10 |
|        | READ   | 9.169904| 7.788333 | 7.80E-11| 1.43E-09 |
| miR-490| ESCA   | -5.21591| 2.65515 | 5.31E-22| 2.84E-19 |
|        | GAC    | -3.36686| 4.719789 | 2.47E-25| 1.69E-23 |
|        | COAD   | -3.30811| 2.495235 | 9.38E-07| 5.95E-06 |
|        | READ   | -5.02312| 3.0164  | 1.22E-09| 1.88E-08 |
| miR-133a-2| ESCA | -3.91342| 5.746671 | 1.07E-21| 3.87E-19 |
|        | GAC    | -3.19544| 6.478735 | 3.01E-39| 7.88E-37 |
|        | COAD   | -3.09357| 4.728642 | 2.56E-12| 2.86E-11 |
|        | READ   | -4.4379 | 5.079706 | 2.22E-17| 1.09E-15 |

Figure 7: Continued.
processes, for instance, proliferation, apoptosis, differentiation, and metabolism [7]. In addition, miRNAs participate in carcinogenesis and progression of malignant tumors by regulation of cell cycle progression, angiogenesis, cell migration, and invasion [12]. A large number of researches have showed that miRNAs play a vital role and could be used

**Figure 7:** Differential expressions of miR-490, miR-552, and miR-133a-2 in adenocarcinoma of the digestive tract—ESCA (esophageal adenocarcinoma), GAC (gastric adenocarcinoma), COAD (colon adenocarcinoma), and READ (rectal adenocarcinoma). In the boxplot, the abscissa represents the type of cancer and the ordinate represents the log 2 value of the expression. The brownish yellow color represents the tumor sample, and the green color represents the sample of the paracancerous control tissue. (a) miR-490. (b) miR-133a-2. (c) miR-552.

**Figure 8:** ROC curve of the diagnostic value of miR-490, miR-133a-2, and miR-552 in adenocarcinoma of the digestive tract: (a) COAD (colon adenocarcinoma); (b) ESCA (esophageal carcinoma); (c) READ (rectal adenocarcinoma); (d) GAC (gastric adenocarcinoma). The ROC curve was generated by the MedCalc software. The transversal coordinates represent 100–specificity, and the ordinate is sensitivity.
as an independent prognosis factor in cancers [13–16]. Some exosomal miRNAs are considered stable biomarkers of tumor disease and play a critical role in carcinogenesis and cancer progression. Exosomal miR-6803-5p could act as a biomarker for diagnosis and prognosis through detecting the level of exosomal miRNA in the serum of the CRC patient [17]. Furthermore, Fu et al. [18] indicated that the circulating miR-17-5p and miR-92a-3p were significantly related to the pathological stage and grade in patients with CRC. Thus, miRNAs have unique advantages to serve as novel biomarkers for cancer diagnosis because of their important regulatory functions, superior stability, and relatively small amounts.

In recent years, more and more studies had been reported from the perspective of pan-cancer [19, 20]. Analysis of scientific problems across multiple cancer types, known as pan-cancer analysis, identifies commonalities and differences in different tumors. Chen et al. presented the characterization of a large number of expressed enhancers in a genome-wide analysis of 8928 tumor samples of 33 cancer types [21]. It was rarely reported from the perspective of pan-cancer to analyze the prognostic and diagnostic value of miRNA in digestive tract tumors. We present the prognostic and diagnostic value of microRNAs in digestive tract tumors from the perspective of pan-cancer.

Our study found that miR-7-3, miR-328, and miR-323a were of significant prognostic value in four cancers of the digestive tract. Recently, Huo found that miR-7-3 was an independent prognostic factor in gastric adenocarcinoma (GAC) by analyzing the clinical data of 393 cases of TCGA and the expression data of 1881 miRNAs via Cox regression and univariate analysis. The results showed that the survival time of the miR-7-3 group with high expression was significantly longer than that of the miR-7-3 group with low one (P = 0.01) [22], which was consistent with our study. In addition, a study about cervical cancer showed that hsa-miR-7-3 was a potential prognostic biomarker by discovering that increased expression of hsa-miR-7-3 was significantly associated with shortened survival [23], and functional enrichment analysis showed poor prognosis of hsa-miR-7-3-related target genes, which were mainly enriched in the AMPK pathway.

Also, circulating miRNAs can be applied to predict disease progression of primary CRC, including the serum
miR-328-3p marker, which was correlated with the overall survival (OS) and disease-free survival (DFS) of phase I–III CRC, and the curative effect of adjuvant chemotherapy was also related with the expression of miR-328-3p [24], which was consistent with our results in COAD. Furthermore, miR-328 overexpression inhibits the invasion of side population (SP) cells in the CRC and reverses drug resistance by targeting matrix metallopeptidase 16 (MMP16) and ATP-binding cassette subfamily G member 2 (ABCG2) [25, 26]. On the contrary, Xue et al. discussed the role of miR-328 as a biomarker to predict tumor recurrence by studying the luciferase activity in the simulant of miR-328 with different concentrations. It was found that miR-328 could target CD44, and they showed a negative regulatory relationship between them, which indicated that detecting the expression level of miR-328 could target CD44, and they showed a negative regulatory relationship between them, which indicated that detecting the expression level of miR-328 can be used as a means to predict the prognosis of gastric cancer patients [27]. miR-328 has been found to be associated with the prognosis of a variety of tumors in previous studies. In addition to CRC [28], it also involved in non-small-cell lung carcinoma (NSCLC), nasopharyngeal carcinoma, breast cancer, acute myeloid leukemia, glioma, etc. [29–33]. This is similar to the result of Zhang et al. [27], who studied the correlation between five miRNAs (miR-191, miR-28-3p, miR-145, miR-328, and miR-18a) in the serum of NSCLC patients and the three-year overall survival rate of the two groups. The result showed that miR-328 was differentially expressed in paired tumors and normal tissues ($P < 0.0001$), that the target gene of miR-328 was mainly enriched in inflammatory/immune response pathways and pathways related to chemoradiotherapy and/or targeted treatment resistance, and that the miR-328 signal could play a role as a prognostic factor for patients with advanced NSCLC [29, 34]. Also, Ulivi et al. found that PRKCA, il-1, and c-raf1 were involved in the migration of cancer cells through the mRNA target analysis of miR-328 and that the downregulation of hsa-miR-328-3p and its target genes and transcription factors played a key role in the carcinogenesis of NSCLC [35]. Furthermore, in vitro functional tests of Ma cell lines (U251 and U87) showed that high expression of miR-328 could significantly inhibit the

**Figure 11:** Protein-protein interaction (PPI) network. The interaction between proteins included direct physical interaction and indirect functional correlation. Its connection lines used different color signs to distinguish known interactions, such as experimental and predictive interactions, as well as others. The map has been screened for a single gene interacting with each other.
| Category | Term                                                                 | Count | P value   | Fold enrichment |
|----------|----------------------------------------------------------------------|-------|-----------|-----------------|
| GOTERM_BP | GO:0030574~collagen catabolic process                                  | 8     | 4.16E-05  | 8.463709677     |
| GOTERM_BP | GO:0001764~neuron migration                                           | 9     | 1.60E-04  | 5.805686636     |
| GOTERM_BP | GO:0008284~positive regulation of cell proliferation                  | 19    | 1.94E-04  | 2.760695002     |
| GOTERM_BP | GO:0035987~endodermal cell differentiation                             | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0048863~stem cell differentiation                                  | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0071560~cellular response to transforming growth factor beta stimulus | 6     | 7.44E-04  | 8.290980908     |
| GOTERM_BP | GO:0016477~cell migration                                             | 10    | 0.0010267 | 3.936609152     |
| GOTERM_BP | GO:0043410~positive regulation of MAPK cascade                         | 7     | 0.0012322 | 5.851453604     |
| GOTERM_BP | GO:0043406~positive regulation of MAP kinase activity                 | 6     | 0.0017338 | 6.885729907     |
| GOTERM_BP | GO:0010628~positive regulation of gene expression                     | 12    | 0.002002  | 25.39112903     |
| GOTERM_BP | GO:0010976~positive regulation of neuron projection development        | 7     | 0.0025085 | 5.32548026      |
| GOTERM_BP | GO:0002040~sprouting angiogenesis                                     | 4     | 0.0056932 | 10.83354839     |
| GOTERM_BP | GO:0010954~positive regulation of protein processing                  | 3     | 0.0059884 | 3.311886396     |
| GOTERM_BP | GO:0008201~heparin binding                                            | 11    | 9.92E-05  | 4.813673967     |
| GOTERM_BP | GO:0030574~collagen catabolic process                                  | 8     | 4.16E-05  | 8.463709677     |
| GOTERM_BP | GO:0001764~neuron migration                                           | 9     | 1.60E-04  | 5.805686636     |
| GOTERM_BP | GO:0008284~positive regulation of cell proliferation                  | 19    | 1.94E-04  | 2.760695002     |
| GOTERM_BP | GO:0035987~endodermal cell differentiation                             | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0048863~stem cell differentiation                                  | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0071560~cellular response to transforming growth factor beta stimulus | 6     | 7.44E-04  | 8.290980908     |
| GOTERM_BP | GO:0016477~cell migration                                             | 10    | 0.0010267 | 3.936609152     |
| GOTERM_BP | GO:0043410~positive regulation of MAPK cascade                         | 7     | 0.0012322 | 5.851453604     |
| GOTERM_BP | GO:0043406~positive regulation of MAP kinase activity                 | 6     | 0.0017338 | 6.885729907     |
| GOTERM_BP | GO:0010628~positive regulation of gene expression                     | 12    | 0.002002  | 25.39112903     |
| GOTERM_BP | GO:0010976~positive regulation of neuron projection development        | 7     | 0.0025085 | 5.32548026      |
| GOTERM_BP | GO:0002040~sprouting angiogenesis                                     | 4     | 0.0056932 | 10.83354839     |
| GOTERM_BP | GO:0010954~positive regulation of protein processing                  | 3     | 0.0059884 | 3.311886396     |
| GOTERM_BP | GO:0008201~heparin binding                                            | 11    | 9.92E-05  | 4.813673967     |
| GOTERM_BP | GO:0030574~collagen catabolic process                                  | 8     | 4.16E-05  | 8.463709677     |
| GOTERM_BP | GO:0001764~neuron migration                                           | 9     | 1.60E-04  | 5.805686636     |
| GOTERM_BP | GO:0008284~positive regulation of cell proliferation                  | 19    | 1.94E-04  | 2.760695002     |
| GOTERM_BP | GO:0035987~endodermal cell differentiation                             | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0048863~stem cell differentiation                                  | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0071560~cellular response to transforming growth factor beta stimulus | 6     | 7.44E-04  | 8.290980908     |
| GOTERM_BP | GO:0016477~cell migration                                             | 10    | 0.0010267 | 3.936609152     |
| GOTERM_BP | GO:0043410~positive regulation of MAPK cascade                         | 7     | 0.0012322 | 5.851453604     |
| GOTERM_BP | GO:0043406~positive regulation of MAP kinase activity                 | 6     | 0.0017338 | 6.885729907     |
| GOTERM_BP | GO:0010628~positive regulation of gene expression                     | 12    | 0.002002  | 25.39112903     |
| GOTERM_BP | GO:0010976~positive regulation of neuron projection development        | 7     | 0.0025085 | 5.32548026      |
| GOTERM_BP | GO:0002040~sprouting angiogenesis                                     | 4     | 0.0056932 | 10.83354839     |
| GOTERM_BP | GO:0010954~positive regulation of protein processing                  | 3     | 0.0059884 | 3.311886396     |
| GOTERM_BP | GO:0008201~heparin binding                                            | 11    | 9.92E-05  | 4.813673967     |
| GOTERM_BP | GO:0030574~collagen catabolic process                                  | 8     | 4.16E-05  | 8.463709677     |
| GOTERM_BP | GO:0001764~neuron migration                                           | 9     | 1.60E-04  | 5.805686636     |
| GOTERM_BP | GO:0008284~positive regulation of cell proliferation                  | 19    | 1.94E-04  | 2.760695002     |
| GOTERM_BP | GO:0035987~endodermal cell differentiation                             | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0048863~stem cell differentiation                                  | 5     | 6.14E-04  | 12.53882915     |
| GOTERM_BP | GO:0071560~cellular response to transforming growth factor beta stimulus | 6     | 7.44E-04  | 8.290980908     |
| GOTERM_BP | GO:0016477~cell migration                                             | 10    | 0.0010267 | 3.936609152     |
| GOTERM_BP | GO:0043410~positive regulation of MAPK cascade                         | 7     | 0.0012322 | 5.851453604     |
| GOTERM_BP | GO:0043406~positive regulation of MAP kinase activity                 | 6     | 0.0017338 | 6.885729907     |
| GOTERM_BP | GO:0010628~positive regulation of gene expression                     | 12    | 0.002002  | 25.39112903     |
| GOTERM_BP | GO:0010976~positive regulation of neuron projection development        | 7     | 0.0025085 | 5.32548026      |
| GOTERM_BP | GO:0002040~sprouting angiogenesis                                     | 4     | 0.0056932 | 10.83354839     |
| GOTERM_BP | GO:0010954~positive regulation of protein processing                  | 3     | 0.0059884 | 3.311886396     |
| GOTERM_BP | GO:0008201~heparin binding                                            | 11    | 9.92E-05  | 4.813673967     |
proliferation, invasion, and migration of two types of glial cells, and miR-328 could inhibit the invasion and proliferation of malignant cells, indicating a good prognosis for glioma [36]. Similarly, Wu et al. established the expression profile of miRNAs related to miR-328 with 60 GBM samples and identified the gene set closely related to cell mitosis. It was found that the ectopic expression of miR-328 blocked the spreading, adhesion, and proliferation of U87 cells and induced the arrest of the U87 cell division cycle, suggesting the decreased expression of miR-328 in high-level glioma was found that the ectopic expression of miR-328 blocked proliferation, invasion, and migration of two types of glial cells, and miR-328 could inhibit the invasion and proliferation of malignant cells, indicating a good prognosis for glioma [36]. Similarly, Wu et al. established the expression profile of miRNAs related to miR-328 with 60 GBM samples and identified the gene set closely related to cell mitosis. It was found that the ectopic expression of miR-328 blocked the spreading, adhesion, and proliferation of U87 cells and induced the arrest of the U87 cell division cycle, suggesting the decreased expression of miR-328 in high-level glioma associated with poor survival [33]. In a word, miR-328 can be applied to the diagnosis, prognosis, and treatment of CRC metastasis. Nevertheless, further studies are needed to verify its effectiveness, such as epidemiological and clinical researches.

As for the prognosis factor of miR-323a, there is still no research showing the intrinsic relationship between miR-323a and digestive tract tumors. Our study is the first one to suggest that miR-323a was a protective factor in CRC. But other cancer studies have shown that miR-323a can be used as a prognostic marker for acute coronary syndrome (ACS), cervical cancer, and glioblastoma [37–39]. Pilbrow et al. investigated the level of circulating miRNAs in patients with ACS and studied the relationship between circulating miRNAs and neurohormones, cardiac structure, and function as well as the 5-year follow-up period. It was found that miR-323-3p circulating in ACS patients was significantly increased at least one year later and could be a stable biomarker of ACS [37]. In addition, the increased expression level of miR-323-3p may contribute to the activation of metastatic potential of cervical cancer and may be involved in cell adhesion, cytoskeleton remodeling, and cell proliferation and migration by targeting metastasis-related genes to regulate the steps of the metastasis cascade [38]. In addition, as a prognostic indicator for glioblastoma patients, it has been found that the recurrence of glioblastoma relates to the genes concerning migration and adhesion targeted by miR-323, and the low level of miR-323 is associated with long OS. Furthermore, survival analysis showed that the expression level of miR-323 was increased in patients with nonrecurrence or long recurrence time [39].

Moreover, the diagnostic ability of miRNAs in cancers of the digestive tract has been widely reported. Zeng et al. [40] explored the diagnostic and prognostic value of miRNAs in ESCA based on the TCGA data and found the combined AUC of five miRNAs (miRNA-93, miRNA-21, miRNA-4746, miRNA-196a-1, and miRNA-196a-2) was 0.985. In addition, Wang et al. [41] identified four miRNAs were related to GAC pathogenesis based on 130 patients using qRT-PCR. The AUC values of miR-106a-5p and miR-19b-3p were 0.786 and 0.786, respectively. Similarly, Liu et al. [42] detected the expression of miR-21, miR-29a, miR-125b, and miR-223 in 85 patients with CRC utilizing qRT-PCR, evaluated their diagnostic value, and found the combined AUC of the miRNA was 0.952. Compared with above previous studies, the present study investigated the

| Category | Term | Count | P value | Fold enrichment | Bonferroni correction | Benjamini correction | P |
|----------|------|--------|---------|-----------------|----------------------|---------------------|---|
| GOTERM MF | GO:0004114~3’,5’-cyclic-nucleotide phosphodiesterase activity | 3 | 0.0418623 | 9.136388237 |
| GOTERM MF | GO:0016167~glial cell-derived neurotrophic factor receptor activity | 2 | 0.0420504 | 46.69709544 |
| GOTERM MF | GO:0003707~steroid hormone receptor activity | 4 | 0.0494637 | 4.830734011 |

| Term | Count | P value | Fold enrichment | Bonferroni correction | Benjamini correction | P |
|------|--------|---------|-----------------|----------------------|---------------------|---|
| hsa04515:PI3K-Akt signaling pathway | 15 | 3.65E-04 | 3.004348 | 0.058823 | 0.058823 | 0.442772 |
| hsa04015:Rap1 signaling pathway | 10 | 0.00302 | 3.290476 | 0.394725 | 0.222006 | 3.608333 |
| hsa05146:Amoebiasis | 7 | 0.003999 | 4.563208 | 0.485801 | 0.198856 | 4.752072 |
| hsa04014:Ras signaling pathway | 10 | 0.004906 | 3.057522 | 0.558 | 0.184629 | 5.801109 |
| hsa04510:Focal adhesion | 9 | 0.009149 | 3.018932 | 0.782528 | 0.262978 | 10.56663 |
| hsa05200:Pathways in cancer | 13 | 0.010028 | 2.285751 | 0.812318 | 0.243334 | 11.52584 |
| hsa04915:Estrogen signaling pathway | 6 | 0.01351 | 4.187879 | 0.895431 | 0.275706 | 15.23378 |
| hsa04514:Cell adhesion molecules (CAMs) | 7 | 0.015913 | 3.406338 | 0.930252 | 0.283128 | 17.70954 |
| hsa04921:Oxytocin signaling pathway | 7 | 0.02547 | 3.061392 | 0.986195 | 0.37865 | 26.91053 |
| hsa04670:Leukocyte transendothelial migration | 6 | 0.026761 | 5.135559 | 0.988922 | 0.362551 | 28.07849 |
| hsa04512:ECM-receptor interaction | 5 | 0.035749 | 3.971264 | 0.997625 | 0.42268 | 35.74616 |
| hsa04974:Protein digestion and absorption | 5 | 0.037053 | 3.926136 | 0.998103 | 0.406844 | 36.794 |
| hsa04611:Platelet activation | 6 | 0.038344 | 3.189231 | 0.585041 | 0.218777 | 28.07849 |
| hsa05320:Morphone addiction | 5 | 0.04128 | 3.796703 | 0.999062 | 0.392237 | 39.9686 |
| hsa04530:Tight junction | 6 | 0.046329 | 3.026277 | 0.99962 | 0.408424 | 43.80734011 |

Table 4: Continued.
diagnostic ability of 3 miRNAs (miR-490, miR-133a-2, and miR-552) in pan-cancer of the digestive tract together.

miR-490 has been reported in many digestive tract tumors, such as GAC [43, 44] and CRC [45–47]. Qu et al. [43] detected the expression level of miR-490-3p in GAC patients by qRT-PCR. The result showed that miR-490-3p was downregulated. The expression level of miR-490-3p in Helicobacter pylori- (HP-) positive GAC was significantly associated with lymph node metastasis and tumor differentiation. In addition, 5-year overall survival of GAC patients with low miR-490-3p expression was shortened in the HP-positive cohort, and multivariate analysis indicated that low expression of miR-490-3p was an independent risk factor in HP-positive GAC. Also, Tang et al. [48] found that miR-490 expression was downregulated in cancers of the digestive tract by analyzing 1,765 tumor samples in TCGA. The study of Zheng et al. [45] revealed that hypermethylation of the miR-490-3p promoter downregulated the expression of miR-490-3p in colorectal cancer, which revealed that miR-490-3p suppresses the proliferation of tumor cells by inducing apoptosis and inhibits the initiation of epithelial-mesenchymal transition (EMT) in vitro and in vivo, indicating that its expression was continuously downregulated in CRC malignancy and CRC cell lines. The ability of migration and invasion in tumor cells was inhibited if miR-490-3p was oversuppressed, and the opposite effect was produced by knocking down miR-490-3p. Further studies found that it can inhibit CRC cell migration and invasion by targeting the TGF-β signaling pathway [46]. For miR-133a-2, however, the study of its function in tumors is rare in recent years, and only GAC [49], CRC [50], and bladder cancer [51] have been reported. Chen et al. [49] found that the AUC of miR-133a-2 in GAC was 0.905, and the sensitivity and specificity were 76.75% and 92.68% based on the TCGA data. miR-133a-2 showed significant correlation between race, tumor grade, tumor pathology, metastasis, and tumor stage.
In addition, miR-133a-2 was less expressed in the early stage (T1/T2 grade and I/II tumor stage) and was significantly higher in the late stage ($P < 0.05$), which suggested that miR-133a-2 may be a new potential predictor in the tumor stage. miR-552 function in CRC has been widely reported [52–56], and it has also been studied in lung tumor [57], breast tumor [58], and pancreatic cancer [59]. Wang and Liu [52] suggested that miR-552 was highly expressed in CRC through qRT-PCR experiments on 183 CRC patients and precancerous tissues, and high expression of miR-552 was significantly related to histological grade, lymph node metastasis, and TNM stage. Overall survival in patients with high expression levels of miR-552 was obviously lower than that in patients with low expression levels of miR-552 ($p = 0.0036$), which indicated high expression of miR-552 was an independent prognostic factor for CRC patients with poor prognosis through univariate and multivariate analysis. Cao et al. [53] found that miR-552 was upregulated in CRC tissues and cell lines by qRT-PCR experiments in 20 pairs of CRC patient tissues and adjacent control tissues and cell lines. miR-552 could be applied as a potential predictor and diagnostic biomarker for CRC. Wang et al. [54] also found that miR-552 was highly expressed in CRC by similar experiments and found that miR-552 promotes CRC metastasis by targeting ADAM28, which suggested miR-552 may serve as a new target for CRC therapy. miR-552 was highly expressed in CRC tissues in analysis of 25 cases of CRC and 10 cases of normal colorectal using qRT-PCR [56], and it was found to be related to the clinical stage and distant metastasis ($p < 0.05$).

In this study, 3 DEMIs (miR-490, miR-133a-2, and miR-552) exhibited high diagnostic ability in READ and moderate diagnostic ability in ESCA, GAC, and COAD. The expressions of miR-490 and miR-133a-2 were downregulated, and miR-552 was upregulated in cancers of the digestive tract. Our results were consistent with the former studies and validated through analysis of the Gene Expression Omnibus (GEO) DataSets. To summarize, the significant prognostic value of miR-490, miR-133a-2, and miR-552 in ESCA, GAC, COAD, and READ provided solid reasons for being therapeutic targets for patients with pancreatic cancer of the digestive tract, for which the novel prognosis and candidates may serve certain functions in process of tumor development, as predicted.

Increasing evidence has demonstrated that new diagnostic or therapeutic targets could be obtained, and new insight into the molecular mechanisms of tumor development may be provided through network regulation and signaling pathway analysis [40, 45, 53, 60, 61]. So we construct the miRNA-gene network and further explore the biological process and pathways in which the target genes could be participated. We perform the PPI network analysis, GO annotation and KEGG pathway analysis, and gene group RIDA analysis. 22 hub genes were identified by PPI network analysis, and G protein γ subunit 7 (GNM7) was most active. GNG7 is the target gene of miR-552, but the relationship

![Figure 13: Analysis of related diseases of the 281 target genes. In the analysis of related diseases, it was suggested that these genes are concentrated in tumors, tumor metastasis, adenocarcinoma, death, gastric cancer, colorectal cancer, and other diseases.](image)
between GNG7 and miR-552 is unclear. The team of surgeons at Kyushu University in Japan has explored the role of GNG7 in different tumors. They found that GNG7 was downregulated in pancreatic cancer, gastric cancer, intrahepatic cholangiocarcinoma, esophageal cancer, and CRC [62–65]. They also found that the expression of GNG7 was significantly repressed by miR-328 and the suppression of GNG7 was associated with great invasiveness and poor prognosis [65]. Then, we supposed that the upregulated miR-552 might suppress the expression of GNG7 to promote the development of cancers of the digestive tract; however, this hypothesis needs to be confirmed with in vitro and in vivo experiments in future. In these hub genes, CXCL12 has been reported to be related to poor prognosis in ESCA [66]. We previously identified CXCL12 as one of the hub genes in ESCA with 187 cases based on TCGA data [40]. The GO annotation analysis of the 281 overlapping genes suggested that the target genes mainly participate in positive regulation of cell proliferation and play their molecular role by heparin binding. The KEGG pathways were also identified, such as PI3K-Akt signaling pathway, Rap1 signaling pathway, and pathways in cancer, which play a key role in the occurrence and development of cancers of the digestive tract. In the gene group RIDA analysis, the target genes were related to neoplasm, neoplasm metastasis, stomach neoplasm, and colorectal neoplasm. In addition, analysis of the core network indicated the relationship of activation, inhibition, and ubiquitination between these target genes. In the analysis of related transcription factors, the target genes were significantly enriched in DNA binding, activation, and inhibition. All the results of bioinformatics analysis demonstrated that these three miRNAs might influence the tumorigenesis and deterioration of tumors by targeting manifold genes and pathways. The target genes might play their role in the occurrence and development of cancers of the digestive tract through a number of biological processes, gene and gene interconnections, and the regulation of transcription factors. The results in this
Figure 15: Analysis of related transcription factors. This analysis suggested that the transcription factors regulate DNA binding, transcription factor regulation-activation, and transcription factor regulation-inhibition.
Figure 16: Verification of the differential expression of the three prognostic miRNAs from Gene Expression Omnibus (GEO) DataSets. (a) GSE89974. (b) GSE114110. (c) GSE93415. (d) GSE89974. (e) GSE89974. (f) GSE114110. (g) GSE89974. CRC: colorectal cancer; ESCA: esophageal carcinoma; GAC: gastric adenocarcinoma.

Figure 17: Verification of the expression of the three differentially expressed miRNAs based on Gene Expression Omnibus (GEO) DataSets. (a) GSE89974. (b) GSE55856. (c) GSE93415. (d) GSE89974. (e) GSE114110. (f) GSE30070. (g) GSE89974. (h) GSE66274. (i) GSE30070. CRC: colorectal cancer; ESCA: esophageal carcinoma; GAC: gastric adenocarcinoma.
The present study gave us a direction to further explore the molecular mechanisms of the three miRNAs in the development of cancers of the digestive tract by using the experimental technique.

5. Conclusion

To summarize, we identified three DEMIs (miR-7-3, miR-328, and miR-323a) which are of significant prognostic value and three DEMIs (miR-490-3p, miR-133a-3p, and miR-552-3p) with high diagnostic ability in READ and moderate diagnostic ability in ESCA, GAC, and COAD by analyzing the miRNA expression profiles in a large number of samples from the TCGA database and GEO DataSets. A total of 281 target genes were also found, and they were used to perform a number of biological function analyses. The results indicated that variant genes and signaling pathways were targeted by these three DEMIs in cancers of the digestive tract. However, in vitro and in vivo experimentally functional verification was needed for target gene functional analysis in the present study. From the perspective of pan-cancer, our study may provide significant contribution to...
validation studies and bring the diagnostic and prognostic miRNAs or target genes to clinics in the future.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by funding from the Nanning Scientific Research and Technical Development Project (20133182), Guangxi Health Department Research Project (Z2014458, Z2013401, and Z2013675), and Guangxi Natural Science Foundation Project (2018GXNSFAA050150).

Supplementary Materials

Supplementary Table 1: predictive values of related clinical parameters. The clinicopathological parameters from patients with colon cancer were obtained from the TCGA data portal (https://portal.gdc.cancer.gov/). These data were matched with miRNA expression values, and parameters of 431 colon cancer patients were obtained. The clinicopathological parameters include gender, age, disease stage, T stage, N stage, M stage, lymphatic invasion, venous invasion, perineural invasion, treatment outcome, neoplasm recurrence, residual tumor, BMI, radiation therapy, and tumor status. Meanwhile, the prognostic value of a diversity of clinicopathological parameters was also explored. It was demonstrated by univariate Cox regression analysis that gender, disease stage, N stage, M stage, lymphatic invasion, venous invasion, treatment outcome, neoplasm recurrence, residual tumor, and tumor status were associated with the prognosis of colon cancer. (Supplementary Materials)

References

[1] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[2] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[3] M.-M. He, F. Wang, Y. Jin et al., “Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer,” Cancer Science, vol. 109, no. 11, pp. 3575–3582, 2018.
[4] B. E. C. Fava, W. L. da Costa Jr., M. L. L. Medeiros et al., “Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center,” World Journal of Surgical Oncology, vol. 16, no. 1, p. 62, 2018.
[5] H. Tanaka, S. Hazama, M. Iida et al., “miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer,” Cancer Science, vol. 108, no. 11, pp. 2229–2238, 2017.
[6] M. F. Souza, H. Kuasne, M. C. Barros-Filho et al., “Circulating miRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer,” PLoS One, vol. 12, no. 9, Article ID e0184094, 2017.
[7] F. Lovat, N. Valeri, and C. M. Croce, “MicroRNAs in the pathogenesis of cancer,” Seminars in Oncology, vol. 38, no. 6, pp. 724–733, 2011.
[8] C. J. Cheng, R. Bahal, I. A. Babar et al., “MicroRNA silencing for cancer therapy targeted to the tumour microenvironment,” Nature, vol. 518, no. 7537, pp. 107–110, 2015.
[9] Z. Zhang and D.-Q. Dai, “MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promoter demethylation,” World Journal of Gastroenterology, vol. 25, no. 10, pp. 1224–1237, 2019.
[10] L. H. Yao, G. R. Wang, Y. Cai et al., “The expressions and diagnostic values of miR-18a and miR-21 in esophageal cancer,” Zhonghua Zhong Liu Za Zhi, vol. 41, no. 2, pp. 107–111, 2019.
[11] X. Xi, M. Teng, L. Zhang, L. Xia, J. Chen, and Z. Cui, “MicroRNA-204-3p represses colon cancer cells proliferation, migration, and invasion by targeting HMGA2,” Journal of Cellular Physiology, 2019.
[12] L. Fabris, Y. Ceder, A. M. Chinnaiyan et al., “The potential of MicroRNAs as prostate cancer biomarkers,” European Urology, vol. 70, no. 2, pp. 312–322, 2016.
[13] P. Li, Q. Ou, T. A. Braciak, G. Chen, and F. S. Oduncu, “MicroRNA-192-5p is a predictive biomarker of survival for stage IIIIB colon cancer patients,” Japanese Journal of Clinical Oncology, vol. 48, no. 7, pp. 619–624, 2018.
[14] T. Jiang, L. Ye, Z. Han et al., “miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses,” Journal of Experimental & Clinical Cancer Research, vol. 36, no. 1, p. 131, 2017.
[15] J. Yang, D. Ma, A. Fesler et al., “Expression analysis of microRNA as prognostic biomarkers in colorectal cancer,” Oncotarget, vol. 8, no. 32, pp. 52403–52412, 2017.
[16] F. Tong, Y. Ying, H. Pan, W. Zhao, H. Li, and X. Zhan, “MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC),” Bosnian Journal of Basic Medical Sciences, vol. 18, no. 3, pp. 252–259, 2018.
[17] S. Yan, Y. Jiang, C. Liang et al., “Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer,” Journal of Cellular Biochemistry, vol. 119, no. 5, pp. 4113–4119, 2018.
[18] F. Fu, W. Jiang, L. Zhou, and Z. Chen, “Circulating exosomal mir-17-5p and mir-92a-3p predict pathologic stage and grade of colorectal cancer,” Translational Oncology, vol. 11, no. 2, pp. 221–232, 2018.
[19] J. Liu, T. Lichtenberg, K. A. Hoadley et al., “An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics,” Cell, vol. 173, no. 2, pp. 400–416 e11, 2018.
[20] X. Ma, Y. Liu, Y. Liu et al., “Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours,” Nature, vol. 555, no. 7696, pp. 371–376, 2018.
[21] H. Chen, C. Li, X. Peng et al., “A pan-cancer analysis of enhancer expression in nearly 9000 patient samples,” Cell, vol. 173, no. 2, pp. 386–399 e12, 2018.
[22] Q. Huo, "Analysis of expression profile of miRNA in stomach adenocarcinoma," *Journal of BUON*, vol. 22, no. 5, pp. 1154–1159, 2017.
[23] Y. Zeng, K.-X. Wang, H. Xu, and Y. Hong, "Integrative miRNA analysis identifies hsa-miR-3154, hsa-miR-7-3, and hsa-miR-600 as potential prognostic biomarker for cervical cancer," *Journal of Cellular Biochemistry*, vol. 119, no. 2, pp. 1558–1566, 2018.
[24] D. Ji, M. Qiao, Y. Yao et al., "Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients," *EBioMedicine*, vol. 35, pp. 189–197, 2018.
[25] X. T. Xu, Q. Xu, J. L. Tong et al., "MicroRNA expression correlates with chemotherapy in colorectal cancer patients," *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 4, pp. 1675–1679, 2014.
[26] S. Qiu, S. Lin, D. Hu, Y. Feng, Y. Tan, and Y. Peng, "Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients," *Journal of Translational Medicine*, vol. 11, no. 1, p. 10, 2013.
[27] J. H. Zeng, D. D. Xiong, Y. Y. Pang et al., "Identification of molecular targets for esophageal carcinoma diagnosis using microRNA-seq and RNA-seq data from the cancer genome atlas: a study of 187 cases," *Oncotarget*, vol. 8, no. 22, pp. 35681–35699, 2017.
[28] K. Wang, M. Chen, and W. Wu, "Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer," *World Journal of Surgical Oncology*, vol. 15, no. 1, p. 175, 2017.
[29] S. Zhang, P. Li, L. Zhao, and L. Xu, "LINC00210 as a miR-328-5p sponge promotes nasopharyngeal carcinoma tumorigenesis by activating NOTCH3 pathway," *Bioscience Reports*, vol. 38, no. 6, Article ID BS20181168, 2018.
[30] N. Al-Othman, H. Hammad, and M. Ahram, "Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells," *Gene*, vol. 675, pp. 128–135, 2018.
[31] L. Liu, R. Chen, Y. Zhang, W. Fan, F. Xiao, and X. Yan, "Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia," *Diagnostic Pathology*, vol. 10, no. 1, p. 109, 2015.
[32] Z. Wu, L. Sun, H. Wang et al., "MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma," *PLoS One*, vol. 7, no. 6, Article ID BS20181168, 2012.
[33] Y. Zhang, J. A. Roth, H. Yu et al., "A 5-MicroRNA signature identified from serum MicroRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer," *Carcinogenesis*, vol. 40, no. 5, pp. 643–650, 2018.
[34] P. Ulivi, G. Foschi, M. Mengozzi et al., "Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC," *International Journal of Molecular Sciences*, vol. 14, no. 5, pp. 10332–10342, 2013.
[35] J. Yuan, Z. Zheng, Y. Zheng, X. Lu, L. Xu, and L. Lin, "microRNA-328 is a favorable prognostic marker in human glioma via suppressing invasive and proliferative phenotypes of malignant cells," *International Journal of Neuroscience*, vol. 126, no. 2, pp. 145–153, 2016.
[36] A. P. Pilbrow, L. Cordeddu, V. A. Cameron et al., "Circulating miR-323-3p and miR-652: candidate markers for the presence and progression of acute coronary syndromes," *International Journal of Cardiology*, vol. 176, no. 2, pp. 375–385, 2014.
[37] H. Ding, Y.-L. Wu, Y.-X. Wang, and F.-F. Zhu, "Characterization of the microRNA expression profile of cervical squamous cell carcinoma metastases," *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 4, pp. 1675–1679, 2014.
[38] S. Chen, J. Zhu, F. Yu, Y. Tian, S. Ma, and X. Liu, "Combination of miRNA and RNA functions as potential biomarkers for gastric cancer," *Journal of Translational Medicine*, vol. 11, no. 1, p. 10, 2013.
colorectal cancer,” *European Review for Medical and Pharmacological Sciences*, vol. 22, no. 2, pp. 412–416, 2018.

[53] J. Cao, X.-R. Yan, T. Liu et al., “MicroRNA-552 promotes tumor cell proliferation and migration by directly targeting DACH1 via the Wnt/β-catenin signaling pathway in colorectal cancer,” *Oncology Letters*, vol. 14, no. 3, pp. 3795–3802, 2017.

[54] J. Wang, H. Li, Y. Wang et al., “MicroRNA-552 promotes tumor cell proliferation and migration by directly targeting DACH1 via the Wnt/β-catenin signaling pathway in colorectal cancer,” *Oncology Letters*, vol. 14, no. 3, pp. 3795–3802, 2017.

[55] Z.-S. Xia, L. Wang, T. Yu et al., “MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer,” *Oncology Reports*, vol. 32, no. 2, pp. 589–596, 2014.

[56] W. G. Chen, M. S. Lin, Y. L. Ye, H. J. Gao, Z. Y. Song, and X. Y. Shen, “microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer,” *Experimental and Therapeutic Medicine*, vol. 3, no. 6, pp. 1039–1048, 2012.

[57] J. Kim, N. J. Lim, S. G. Jang, H. K. Kim, and G. K. Lee, “miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal cancer metastases in the lung,” *Anticancer Research*, vol. 34, no. 5, pp. 2297–2302, 2014.

[58] S.-K. Leivonen, K. K. Sahlberg, R. Mäkelä et al., “High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth,” *Molecular Oncology*, vol. 8, no. 1, pp. 93–104, 2014.

[59] Y. G. Park, K. H. Lee, J. K. Lee et al., “MicroRNA expression pattern in intraductal papillary mucinous neoplasm,” *The Korean Journal of Gastroenterology*, vol. 58, no. 4, pp. 190–200, 2011.

[60] J. Liu, F. Liu, Y. Shi, H. Tan, and L. Zhou, “Identification of key miRNAs and genes associated with stomach adenocarcinoma from the cancer genome atlas database,” *FEBS Open Bio*, vol. 8, no. 2, pp. 279–294, 2018.

[61] S. Wu, F. Wu, and Z. Jiang, “Identification of hub genes, key miRNAs and potential molecular mechanisms of colorectal cancer,” *Oncology Reports*, vol. 38, no. 4, pp. 2043–2050, 2017.

[62] K. Shibata, M. Mori, S. Tanaka, S. Kitano, and T. Akiyoshi, “Identification and cloning of human G-protein γ7, down-regulated in pancreatic cancer,” *Biochemical and Biophysical Research Communications*, vol. 246, no. 1, pp. 205–209, 1998.

[63] T. Utsunomiya, H. Inoue, K. Taguchi, M. Shimada, K. Sugimachi, and M. Mori, “G protein γ7 expression as a new clinicopathological marker in patients with intrahepatic cholangiocarcinoma,” *Archives of Surgery*, vol. 137, no. 2, pp. 181–185, 2002.

[64] K. Shibata, S. Tanaka, T. Shiraishi, S. Kitano, and M. Mori, “G-protein gamma 7 is down-regulated in cancers and associated with p27kip1-induced growth arrest,” *Cancer Research*, vol. 59, no. 5, pp. 1096–1101, 1999.

[65] M. Ohta, K. Mimori, Y. Fukuyoshi et al., “Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer,” *British Journal of Cancer*, vol. 98, no. 2, pp. 410–417, 2008.

[66] Y. Uchi, H. Takeuchi, S. Matsuda et al., “CXCL12 expression promotes esophageal squamous cell carcinoma proliferation and worsens the prognosis,” *BMC Cancer*, vol. 16, no. 1, p. 514, 2016.